Jaguar Health, Inc.
JAGX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | 0.00 | 0.00 | -0.01 |
| FCF Yield | -132.99% | -242.17% | -245.27% | -108.12% |
| EV / EBITDA | -4.41 | -4.14 | -3.55 | -2.28 |
| Quality | ||||
| ROIC | -19.43% | -21.14% | -22.35% | -17.71% |
| Gross Margin | 82.51% | 82.31% | 78.26% | 84.13% |
| Cash Conversion Ratio | 0.49 | 0.59 | 0.70 | 0.79 |
| Growth | ||||
| Revenue 3-Year CAGR | 3.20% | 2.22% | 0.73% | -0.75% |
| Free Cash Flow Growth | 24.29% | 15.35% | 9.02% | -27.13% |
| Safety | ||||
| Net Debt / EBITDA | -3.92 | -3.80 | -3.25 | -1.81 |
| Interest Coverage | 1,206.33 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.05 | 0.05 | 0.05 | 0.05 |
| Cash Conversion Cycle | 412.17 | 740.29 | 673.95 | 859.68 |